Masoud Keikha - Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran- Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Mohsen Karbalaei - Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran

As youknow,humanT-lymphotropic virus type ۱ (HTLV-۱), as a type C retrovirus was first isolated from patients involvedwith cutaneous T-cell lymphoma in ۱۹۸۰ (۱). Fromamong all of infected individuals by this virus, approximately۹۰% remain asymptomatic; some ۵% developedto acute status, adult T cell leukaemia/lymphoma (ATLL),and about ۴% developed to chronic status, as namedHTLV-۱-associated myelopathy/tropical spastic paraparesis(HAM/TSP), which causes a viral progressive paralysis. Further,about ۱% of individuals are afflicted to uveitis (HU)and other diseases with unestablished associations suchas arthropathy, pneumopathy, dermatitis, exocrinopathyand myositis (۲, ۳). HTLV-۱ protease (PR) as a homodimeraspartic protease, has a pivotal role for maturation of infectedvirus. Nowadays, designing of protease inhibitorcomposition, has been focused on the blocking of proteaseactivity (۴).